Related Experiment Videos
[Interferon alpha and infantile orbital hemangioma]
B Damas Mateache1, J J Menéndez Suso, J M Abelairas Gómez
1Servicios de Oftalmología y Pediatria General del Hospital Universitario La Paz, Madrid, Spain.
Archivos De La Sociedad Espanola De Oftalmologia
|December 4, 2003
Summary
Interferon alpha therapy effectively reduced infantile periorbital hemangiomas, with significant volume reduction in most cases. While generally safe, potential adverse effects like transient spastic diplegia and lipid profile changes require monitoring.
Area of Science:
- Ophthalmology
- Pediatric Dermatology
- Pharmacology
Context:
- Infantile periorbital hemangiomas (IPHs) can cause significant visual impairment.
- Limited treatment options exist for IPHs, necessitating exploration of effective therapies.
Purpose:
- To evaluate the efficacy and safety of interferon alpha (IFN-α) therapy for infantile periorbital hemangiomas.
- To assess the impact of IFN-α on lesion size and associated visual impairment.
Summary:
- A retrospective study analyzed 4 infants with orbital hemangiomas treated with subcutaneous interferon alpha 2b (3 million U/m²/day for at least 3.5 months).
- Significant lesion volume reduction (≥50%) was observed in all patients, with 95% reduction in three cases.
- Adverse effects included transient spastic diplegia in one child and altered lipid profiles in another, both resolving after treatment cessation.
Impact:
- Interferon alpha demonstrates potential as a valuable therapeutic option for infantile periorbital hemangiomas.
- Clinically significant adverse effects associated with interferon alpha therapy necessitate careful patient monitoring.